Access cutting-edge myelofibrosis treatment through this clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.
Access myelofibrosis specialists in Phoenix at no cost
This study follows strict safety protocols and ethical guidelines
All study-related myelofibrosis treatment provided free
This is an open label, multicenter, phase 2 trial of Canakinumab in patients with primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF). Eligible patients will receive Canakinumab administered as a subcutaneous injection on day 1 of a 21 day cycle for a core study period of 8 cycles. Canakinumab will be given by subcutaneous injection (SC) injection at a starting dose of 200 mg (one 150 mg/mL syringe and one 50 mg/0.5 mL syringe) every 3 weeks.
Sponsor: John Mascarenhas
Check if you qualify for this myelofibrosis clinical trial in Phoenix, AZ
If you're searching for myelofibrosis treatment options in Phoenix, AZ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Phoenix research site is actively enrolling participants for this clinical trial. You'll receive care from experienced myelofibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.